People with HIV who had detectable viral load at the time of vaccination produced lower levels of antibodies after two doses of the Pfizer SARS-CoV-2 vaccine, researchers from Sweden’s Karolinska Institute report in the journal AIDS. Further research is needed to determine if this group are especially vulnerable to loss of antibody protection.
The findings come from the COVAXID study, which compared responses to the Pfizer vaccine in 90 people living with HIV on antiretroviral therapy and a control group of 90 HIV-negative adults. All participants with HIV were taking antiretroviral therapy, although 14% had detectable viral loads above 50 copies/ml. The median CD4 was 565; just under half (49%) had a lowest-ever CD4 count below 200. People with HIV and the control group were well matched in terms of age, comorbidities and body mass index.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
Infectious Disease Advisor: Breakthrough COVID-19 does not meaningfully affect HIV CD4+ count
-
[Press release] Shionogi announces FDA approval of XOCOVA® (ensitrelvir), the first and only oral option to help prevent COVID-19 following exposure
-
[CROI 2026] HIV i-Base: Nine comprehensive free reviews in Topics in Antiviral Medicine
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.